ArticleGastroenterology report2025
Survival benefit of metastasectomy in colorectal cancer with pulmonary metastasis: a population-based, propensity score matched study.
Article in Gastroenterology report, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A clinical study of the CALLY index and HALP score for evaluating response to FOLFOX in colorectal cancer with lung metastases.American journal of translational research · 2026Article
- Multidimensional impact of venous thromboembolism on survival outcomes in ovarian cancer patients: deconstructing competing risks between thrombosis-related and tumor-related mortality.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The survival benefits of pulmonary metastasectomy (PM) in colorectal cancer (CRC) patients with pulmonary metastasis remain controversial. This study aimed to assess the survival effect of PM on CRC patients with pulmonary metastasis. Methods: Data from CRC patients with pulmonary metastasis were collected from the Surveillance, Epidemiology, and End Results database between 2010 and 2020. A 1:1 propensity score matching (PSM) analysis was employed to minimize heterogeneity between the groups. Kaplan-Meier analysis was performed to evaluate the overall survival (OS) of CRC patients with pulmonary metastasis who underwent PM. Results: A total of 1,399 CRC patients with pulmonary metastasis were included; 140 patients and 1,259 patients underwent PM and did not, respectively. After PSM, there were 140 patients in each group. Patients who underwent PM demonstrated a longer median OS than those who did not, in both the overall cohort and the PSM cohort. In the PSM cohort, the median OS was 51 months (95% confidence interval [CI], 45-64 months) for CRC patients with pulmonary metastasis who underwent PM and 36 months (95% CI, 31-42 months) for those who did not undergo PM. Additionally, Cox proportional hazard models indicated that PM was a significant protective factor for OS in CRC patients with pulmonary metastasis (hazard ratio: 0.57; 95% CI, 0.41-0.80, Conclusion: PM prolongs the survival of CRC patients with pulmonary metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.